Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 11, 2020

SELL
$5.38 - $16.14 $3.79 Million - $11.4 Million
-705,356 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$9.79 - $16.72 $6.91 Million - $11.8 Million
705,356 New
705,356 $8.75 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Jupiter Asset Management LTD Portfolio

Follow Jupiter Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jupiter Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Jupiter Asset Management LTD with notifications on news.